Comparative Pharmacology
Head-to-head clinical analysis: ALTAVERA versus KARIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTAVERA versus KARIVA.
ALTAVERA vs KARIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Terminal elimination half-life is 4.5 hours; in renal impairment (CrCl <30 mL/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive